Oncology (Williston Park). 2012 Jan;26(1):26, 28-9.

Neoadjuvant therapy for HER2-positive early-stage breast cancer: the future is almost here.

Rugo HS.

Source

University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, USA.

Comment on

What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer? [Oncology (Williston Park). 2012]
What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?Von Minckwitz G, Loibl S, Untch M. Oncology (Williston Park). 2012 Jan; 26(1):20-6.

PMID:: 22393793; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Comment

MeSH Terms

Substances

Receptor, erbB-2

LinkOut - more resources

Full Text Sources

ProQuest

Medical

Breast Cancer - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept. [Breast Cancer. 2011]
Review Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.
Iwata H. Breast Cancer. 2011 Apr; 18(2):92-7. Epub 2010 Dec 8.
Improving therapy for HER2-positive cancers through neoadjuvant studies. [Oncology (Williston Park). 2012]
Improving therapy for HER2-positive cancers through neoadjuvant studies.
Krop I. Oncology (Williston Park). 2012 Jan; 26(1):34, 36.
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. [J Clin Oncol. 2006]
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, et al. J Clin Oncol. 2006 Jul 1; 24(19):3019-25. Epub 2006 Jun 5.
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. [J Clin Oncol. 2001]
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, et al. J Clin Oncol. 2001 Sep 15; 19(18):3808-16.
Review HER2-overexpressing breast cancer: time for the cure with less chemotherapy? [Curr Opin Oncol. 2011]
Review HER2-overexpressing breast cancer: time for the cure with less chemotherapy?
Loi S, de Azambuja E, Pugliano L, Sotiriou C, Piccart MJ. Curr Opin Oncol. 2011 Nov; 23(6):547-58.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

Neoadjuvant therapy for HER2-positive early-stage breast cancer: the future is a...
Neoadjuvant therapy for HER2-positive early-stage breast cancer: the future is almost here.
Oncology (Williston Park). 2012 Jan ;26(1):26, 28-9.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Neoadjuvant therapy for HER2-positive early-stage breast cancer: the future is almost here.

Source

Comment on

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information